tradmap

CTKB Cytek Biosciences, Inc.

$5.78 -5.56%

Data as of close

Healthcare · Laboratory Analytical Instruments

Cytek Biosciences, Inc. (CTKB) is a healthcare company in the Laboratory Analytical Instruments industry, with a market capitalization of $751 million. Shares last traded at $5.78, 8.7% below their 52-week high. Over the past year the stock is up 51.5%. Net profit margin is -32.2%, below the peer median of 1.9%. Revenue grew 0.5% year over year.

Market Cap
$751M
Shares Out
130.0M
EPS (TTM)
-$0.63
P/E (TTM)*
—
P/S Ratio
3.63
P/B Ratio
2.33
Dividend / Share
—
Dividend Yield
—
52-Week High
$6.33
52-Week Low
$3.31
Volume (venue)
96,526
Avg Vol (3m, venue)
114,400.73

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-1.87%
1M
-1.37%
3M
+35.36%
6M
+24.17%
YTD
+14.57%
1Y
+51.51%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
54.47
SMA (50)
$5.30
SMA (200)
$4.65
Price vs SMA50
+9.13%
Price vs SMA200
+24.17%
ATR (14)
$0.28

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$207M
Net Income
-$67M
Gross Margin
53.2%
Operating Margin
-21.6%
Net Margin
-32.2%
Return on Equity
-20.7%
Return on Assets
-14.9%
Current Ratio
4.48
Debt / Equity
0.39
Revenue Growth (YoY)
+0.5%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$0.09 2026-08-05
Q1 2026 -$0.15 2026-05-07
Q4 2025 (derived) -$0.35 2026-02-26
FY 2025 -$0.52 2026-02-26
Q3 2025 -$0.04 2025-11-05
Q2 2025 -$0.04 2025-08-06

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Laboratory Analytical Instruments peers

CTKB vs 14 industry peers (Laboratory Analytical Instruments), by market cap. Data as of close

P/S vs peers
3.63 / 4.80 med
-24% discount
Net margin vs peers
-32.2% / 1.9% med
below median
1–14 of 14
AAgilent Technologies$48.5B33.686.5819.5%-1.62%
WATWaters Corporation$44.2B68.719.5113.8%-2.86%
ILMNIllumina, Inc.$34.2B38.267.5519.7%-4.10%
MTDMettler Toledo$33.6B37.148.1421.9%+0.17%
RVTYRevvity$16.9B71.265.818.2%-3.38%
AVTRAvantor, Inc.$10.6B31.351.595.1%-2.86%
BIOBio-Rad Laboratories, Inc.$9.8B44.033.788.6%-1.57%
BRKRBruker Corp$8.5B—2.42-2.0%-2.48%
TXG10x Genomics, Inc.$8.0B—13.01-12.2%-12.14%
ALMRAlamar Biosciences, Inc.$2.0B———-5.48%
CTKBCytek Biosciences, Inc.$751M—3.63-32.2%-5.56%
PACBPacific Biosciences Of California, Inc.$727M———-10.34%
MASS908 Devices Inc.$421M—6.92-57.0%-9.26%
NAUTNautilus Biotechnology, Inc.$302M———-13.50%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.